Redhill adds to manufacturing capacity for COVID-19 treatment

28 January 2021

Specialty biopharma RedHill Biopharma (Nasdaq: RDHL) has announced a manufacturing agreement with Cosmo Pharmaceuticals (SIX: COPN) to further expand manufacturing capacity for opaganib in anticipation of emergency use authorizations.

A global Phase II/III study of opaganib, which has the brand name Yeliva, is ongoing in severe COVID-19 pneumonia, with patients enrolled at more than 30 sites in multiple countries.

"Opaganib is designed to act broadly against different viral strains irrespective of mutations in the spike protein"An interim independent Data and Safety Monitoring Board (DSMB) futility analysis will be conducted in the coming days, evaluating data from the first 135 subjects that have reached the primary endpoint.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK